Breast Cancer Translational Research Laboratory – JC Heuson, Institut Jules Bordet, Boulevard de Waterloo, 125, 1000 Brussels, Belgium. [email protected] Brain metastasis (BM) are increasingly ...

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2 ...

Overall survival in metastatic HER2-positive breast cancer varied by location of brain lesions. Patients with central nervous system (CNS)-only disease had a higher risk of CNS-related death, despite ...

Patients had stable and active brain metastases at baseline in the phase IIIb/IV study. The estimated overall median progression-free survival (PFS) was 17.3 months in patients who received the ...

For women with a specific type of breast cancer known as HER2-positive (HER2+), any residual (leftover) disease after primary ...

Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive ...

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2 ...

HER2-positive breast cancer is driven by HER2 protein overexpression, historically linked to poor outcomes but now improved by targeted therapies. Treatment varies by stage, involving surgery, ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...

The annual San Antonio Breast Cancer Symposium was held from Dec. 9 to 12 in San Antonio. Attendees included medical oncologists, radiation oncologists, researchers, and other health care ...